Drugs / HYML-122
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05241093 | Mar 2022 → Dec 2025 | acute myeloid leukemia | Tarapeutics Science Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05241106 | Sep 2021 → Dec 2025 | acute myeloid leukemia | Tarapeutics Science Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HYML-122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05241106 ↗ |
| Route | Oral | “HYML-122 is administered orally consecutive with 400mg bid or 600mg bid or dose adjusted by DMC judgement in each 28-day treatment cycle.” NCT05241093 ↗ |